Health benefits of meditation: A comprehensive review

Jan 13, 2025

10 likes | 81 Views

Explore the multitude of physical and mental health benefits associated with regular meditation practice. Learn about the latest research findings and how incorporating meditation into your daily routine can improve your overall well-being.

Share Presentation

Embed Code

mckenzie-harmon

Download Presentation

Health benefits of meditation: A comprehensive review

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Lennon et al. Supplementary Information Figure S4

Supplementary Figure 4 Hori et al.

One-dimensional gel electrophoresis (SDS-PAGE)

107 views • 1 slides

Patel et al Supplemental Figure S4

A . Patel et al Supplemental Figure S4. 4.1 ± 1.9. SK-ES-1. 13.0 ± 3.8. SK- N-MC. 0. 4. 12. RASSF1A Fold Induction with 5-AZA treatment. B . 39.5 ± 14.5. SK-ES-1. 185.5 ± 45.6. SK- N-MC. 24.3 ± 5.9. A673. 0. 100. 150. 200. 50. CALCA Fold Induction with 5-AZA treatment.

108 views • 1 slides

Mertens et al., Supplementary Figure

Mertens et al., Supplementary Figure.

68 views • 1 slides

Supplementary Figure 1 Lewis, et al.

Cell Death (Ramos). Untreated. Proliferation (Ramos). hIgG (crosslinked). Dacetuzumab (soluble). Dacetuzumab (crosslinked). Percent Cell Death (apoptotic + necrotic). Crosslinking Ab. Dacetuzumab (soluble). hIgG (crosslinked). Dacetuzumab (crosslinked). CD40 Ligand.

103 views • 1 slides

Nakayama et al. , Supplementary Figure 3

Nakayama et al. , Supplementary Figure 3. HNF4G/ACTB (microarray). HNF4G/ACTB (qRT-PCR). 0.035. 2.0. 0.030. 1.5. 0.025. 0.020. 1.0. 0.015. 0.010. 0.5. 0.005. 0.000. 0.0. SS043. SS043. SS043. SS043. SS043. SS043. SS046. SS046. SS046. SS046. SS046. SS046. SS049. SS049.

71 views • 1 slides

Farmer et al Supplementary Figure 1

Farmer et al Supplementary Figure 1. [ KU0058684] (  M). 1. 2. 0. 1. 0. 0. IC 50 = 1nM. 0.00001. 0.0001. KU0051529 PARP-1 IC 50 = 730nM. 0.001. 0.01. 8. 0. 0.1. 100. 10. 0. 1. % activity. 6. 0. 4. 0. 2. 0. 0. 10 -6. 10 -5. 10 -4. 10 -3. 10 -2. 10 -1. 10 0.

214 views • 7 slides

Supplementary Figure 1. Suzuki et al.

BrdU. DAPI/BrdU. 24 hrs. 24 hrs. 48 hrs. 48 hrs. 72 hrs. 72 hrs. Supplementary Figure 1. Suzuki et al. A. B. Supplementary Figure 2. Suzuki et al. p. CPD. H2AX. Merge. p. (6-4) photo. H2AX. Merge. p. XRCC1. H2AX. Merge. Supplementary Figure 3. Suzuki et al. No UV. 3 min.

192 views • 8 slides

Yoon et al. Supplementary Figure S4

Yoon et al. Supplementary Figure S4. A. B. AGS. MKN-45. N87. AGS. MKN-45. N87. Monolayer. Monolayer. Spheroid/ Scr.shRNA. Spheroid/ DMSO. Spheroid/ Smo.shRNA. Spheroid/ Vismodegib. C. AGS. MKN-45. N87. Monolayer. Spheroid/ DMSO. Spheroid/ Vismodegib. 50 μ m.

113 views • 1 slides

Supplementary Figure S4

3. 3. 2.5. 2.5. atpA. atpE. 2. 2. log2. 1.5. log2. 1.5. 1. 1. 0.5. 0.5. 0. 0. 3. atpB. 3. 2.5. 2.5. 2. atpF. 2. 1.5. log2. log2. 1.5. 1. 1. 0.5. 0.5. 0. 0. 3. 3. 2.5. 2.5. atpC1. atpG. 2. 2. log2. 1.5. 1.5. log2. 1. 1. 0.5. 0.5. 0. 0. 3. 3.

113 views • 1 slides

Supplementary Figure 1 Logan et al

IP Ab. HSF1. we. Irr. p63. HSF1 Int. I. II. III. IV. V. F/l.  Pro. 1-292. 248-393. 1-42. TAD DBD Oligo. +. +. 248-393. 1-42. 1-292.  Pro. GST. Inputs. F/l. +. -. -. Pull down. Supplementary Figure 1 Logan et al.

112 views • 4 slides

Supplementary Figure S4

Supplementary Figure S4. Vpr. 0. 317. 100. 3170. 1000. #1. #3. #4. #15. Input 1000pg. STD-IP (input, pg).

132 views • 1 slides

Oiva et al., Supplementary Figure.

Oiva et al., Supplementary Figure. P < 0.0001. 1000. P < 0.0001. 100. Trypsinogen-3 (  g/L). 10. 1. 0.1. Mild AP. Severe AP. Controls.

145 views • 1 slides

Supplementary Figure 5. Nikolova et al

Supplementary Figure 5. Nikolova et al.

87 views • 1 slides

Bernard et al, Supplementary Figure S4

Bernard et al, Supplementary Figure S4. pTRE. pTRIP-DU3-TRE-MCS. Supplementary Figure S4. The pTRIP-DU3-TRE-MCS lentivector.

115 views • 1 slides

Supplementary Figure 1_Van Looy et al.

76 views • 1 slides

Sansone et al, Supplementary Figure 2

HYPO-7. A. 1 MONTH 6 MONTHS 1 YEAR. B. c. 1 MONTH 6 MONTHS 1 YEAR. HYPO-7. MCF-7 + - + - + - HYPO-7 - + - + - +. DFX 600 m M - +. CA-IX.

248 views • 1 slides

Supplementary Figure S4

Supplementary Figure S4. A. B.

126 views • 1 slides

Figure S4 supplementary

Figure S4 supplementary. h igh. low.

97 views • 1 slides

Supplementary Figure S4

35. 30. 25. 20. events (%). 15. 10. 5. 0. 35. 30. 25. 20. events (%). 15. 10. 5. 0. Supplementary Figure S4.

87 views • 1 slides

Figure S4. Yun et al ., 2014

Figure S4. Yun et al ., 2014. Mock. G 1708 A. SA 14 -14-2 MCV ( Parent ). CNU/LP2 ( virulent strain ). 5 dpi. 3 dpi. 5 dpi. 3 dpi. 5 dpi. 3 dpi. 5 dpi. Amygdaloid area. 200  m. Cerebral cortex. 200  m. Thalamus. 200  m. Hypothalamus. 200  m. Brainstem. 200  m.

100 views • 1 slides

More Related